Company: INMB
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003354
Chunk: 200

Company: Inmune Bio, Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1A
Chunk 200
---
 Our licensors may not successfully prosecute any applications for or maintain intellectual
property to which we have licenses, may determine not to pursue litigation against other companies that are infringing such intellectual
property, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license,
other companies might be able to offer similar products for sale, which could adversely affect our competitive business position and harm
our business prospects. If we lose any of our right to use third-party intellectual property, it could adversely affect our ability to
commercialize our technologies, products or services, as well as harm our competitive business position and our business prospects.

We are dependent on our licensing agreement
with Xencor, and the termination of this agreement would harm our business. 

On October 3, 2017, the Company
entered into a license agreement with Xencor, Inc., which has discovered and developed a proprietary biological molecule that inhibits
soluble tumor necrosis factor. Pursuant to the license agreement, Xencor granted the Company an exclusive worldwide, royalty-bearing license
in licensed patent rights, licensed know-how and licensed materials to make, develop, use, sell and import any pharmaceutical product
that comprises, contains, or incorporates Xencor’s proprietary protein known as XPro that inhibits soluble tumor necrosis factor
(or all modifications, formulations and variants of the licensed protein that specifically bind soluble tumor necrosis factor) alone or
in combination with one or more active ingredients, in any dosage or formulation. If we breach this Agreement, Xencor may be able to terminate
it, which would harm our business.

Our officers and Chairman of the Board own
the company that we license our INKmune patent from. 

On October 29, 2015, we entered
into an exclusive license agreement with Immune Ventures, LLC (Immune Ventures). The license agreement relates to our natural killer program,
INKmune. Immune Ventures is owned by our RJ Tesi, our CEO and Chairman of the Board of Directors, David Moss, our Chief Financial Officer
and Treasurer and Mark Lowdell, our Chief Scientific Officer. Because our officers and directors also own Immune Ventures there may be
an inherent conflict of interest which could result in unanticipated actions that adversely affect us.

Changes in U.S. patent law could diminish
the value of patents in general, thereby impairing our ability to protect our products.

As is the case with other
biopharmaceutical companies, our success is